Breaking News, Collaborations & Alliances

Merck, GSK In Kidney Cancer Alliance

To evaluate combination regimen

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck has initiated a clinical trial to evaluate the combination of its investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. The Phase I/II trial will evaluate the safety and efficacy of MK-3475 and pazopanib in treatment naïve patients with advanced renal cell carcinoma.     The companies have also entered a collaboration to study MK-3475 with pazopanib and other agents in GSK’s portfolio in th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters